Adults at high risk of cardiovascular events without prior MI or stroke.
Conditions
Brief summary
Time to CHD death, MI, or ischemic stroke, whichever occurs first, Time to CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurs first
Detailed description
Time to MI, ischemic stroke, or any ischemia-driven arterial revascularization, Time to CHD death, MI, or any ischemia-driven arterial revascularization, Time to cardiovascular death, MI, or ischemic stroke, Time to CHD death or MI, Time to MI, Time to any ischemia-driven arterial revascularization, Time to CHD death, Time to cardiovasular death, Time to all cause of death, Time to ischemic stroke
Interventions
DRUGPlacebo for AMG 145
DRUGEVOLOCUMAB
Sponsors
Amgen Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to CHD death, MI, or ischemic stroke, whichever occurs first, Time to CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurs first | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to MI, ischemic stroke, or any ischemia-driven arterial revascularization, Time to CHD death, MI, or any ischemia-driven arterial revascularization, Time to cardiovascular death, MI, or ischemic stroke, Time to CHD death or MI, Time to MI, Time to any ischemia-driven arterial revascularization, Time to CHD death, Time to cardiovasular death, Time to all cause of death, Time to ischemic stroke | — |
Countries
Austria, Belgium, Bulgaria, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden
Outcome results
None listed